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Abstract 
Title: A Survey Assessing the Contributing Factors to Substance Abuse 
Treatment in U.S. Corrections Settings  
Authors: Michael Soule, Frederick Altice (Section if Infectious Diseases, 
Department of Internal Medicine, Yale University School of Medicine, New 
Haven, CT) 
Abstract: In light of the dramatic rise in incarceration due to the “War on Drugs,” 
we explored the contributing factors to substance abuse treatment (SAT) 
programming – in particular, evidence-based treatments like medication assisted 
therapy (MAT) – implementation in United States correctional settings (including 
jails, prisons, and community corrections facilities). We hypothesized that current 
funding availability would be the primary factor preventing and contributing to 
program implementation, but further hypothesized that an array of secondary 
factors such as overcrowding, geographic location, facility type, and attitudes and 
knowledge about MAT would also play a role. We mailed a survey to an enriched 
sample of 225 correctional units’ administrators (57 jails, 129 prisons, and 40 
community corrections units) across the country, selecting for units previously 
identified by a national survey as being located in areas particularly likely to be 
affected by high rates of drug-related crime. 54.9% responded. As was 
previously recognized, a majority (81.5%) of units reported some form of SAT 
programming, but low levels of MAT implementation were identified (16.1%, a 
majority of which was methadone). Funding cuts were identified as the most 
pressing barrier to future treatment implementation as well as the greatest 
contributor to recent SAT program closure. However, Other factors, such as 
offender need and recidivism reduction were identified as factors contributing to 
program opening. Some geographic trends were noted, with respondents from 
the Southeastern US reporting less MAT availability as well as less willingness to 
implement it. Some differences were also noted across facility types, with jails 
much more likely than either prisons or community corrections to implement 
MAT. In a multivariate regression model, respondent score on a scale measuring 
attitudes towards methadone programming was the only factor significantly 
associated with current implementation of MAT. Both attitudes score and recent 
increases in SAT-specific budget were significantly associated with a willingness 
to consider implementing MAT in the future. We concluded that the bias towards 
counseling-based programming seen in our study was not unique and, taken 
along with the result that attitudes were more important than funding for current 
MAT implementation, this indicated that facility administrators’ comfort with a 
program was the most important factor and that funding would be allocated 
accordingly. In the interest of expanding evidence-based SAT programming in 
this high-need population, we suggest that a targeted education campaign may 
be useful in improving attitudes, and that pilot programs to show proof of concept 
in regions that lack MAT (Southeast and Southwest) would likewise be beneficial.
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Introduction 
 
 
Overview 
 This work sits at the intersection of public policy and addiction medicine, 
with implications for future programming and policy surrounding treatment of 
substance abuse disorders in the United States. Individuals with substance 
abuse disorders have been the subject of a large public debate over the last 
several decades and many agree that the ways in which we as a society are 
attempting to manage the problems that arise around substance abuse are not 
appropriate. In large part, the United States has been engaged in a “war on 
drugs,” both within and outside of our national borders, which encompasses 
military operations in foreign countries, international policy, and also the 
imprisonment of hundreds of thousands of American citizens. Nationwide, 
governments state and federal have chosen punitive over treatment measures as 
the intervention of choice to try to solve the problem of drug abuse and 
dependence in America. 
This work seeks to illuminate the interaction between politics and drug 
abuse treatment and with an eye towards policy recommendation. Broadly 
speaking, the available evidence strongly indicates that treatment, not 
incarceration, is the optimal policy solution to the problem of American drug 
abuse and addiction. Key to this argument is regarding the incarceration of drug 
users for such crimes as possession of drugs or paraphernalia and the choice to 
punish and not treat as clear policy choices. We encourage the reader also to 
consider drug abuse treatment as a viable, evidence-supported alternative. 
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Experts in the field feel so strongly about this that they call “Punishment alone… 
a futile and ineffective response to drug abuse.”(1) 
This paper seeks to provide two things: a dense, thorough introduction to 
this complex arena and the results of our study on the barriers to the 
implementation of this optimal solution. In the introductory section, terminology 
will be established, neurobiology briefly presented, and prevalence of substance 
abuse disorders presented. With that background, an overview of treatment 
methods will then be discussed. Then, the presence of the drug-involved 
offender in the correctional system will be explored, as will several of the most 
important factors associated with the incarceration of drug-abusing individuals. 
Then, several solutions to this complex issue (including public policy and 
academic pilot models) will be presented. This paper will then present the details 
of our study methods, results, and pertinent discussion. 
 
Substance Abuse and Dependence  
Until recent years, substance use was considered a social harm and 
associated with deficits in personality and individual fortitude.  Over the past few 
decades, there has become increasing evidence for the complex interplay 
between biology, behavior, genetics and environment underlying substance 
dependence and abuse. This has lead to the current understanding that 
substance use disorders are a chronic, relapsing - remitting disease with 
components of chemical dependence as well as habitual patterns and social 
structures surrounding obtaining money for drugs, obtaining drugs, and using 
drugs. There are now well-established diagnostic criteria defining substance 
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dependence and substance abuse as distinct, both of which are clinical 
diagnoses, met by assessing symptoms and signs over a 12-month period. 
Substance dependence is a complex interplay between physiology and 
psychology. Physiologic dependence is a physical requirement for stimulation of 
an individual’s receptors by drug molecules. When drug molecules are not 
available, a withdrawal state ensues. Part of the spectrum of substance 
dependence often includes substance use with the aim of abrogating withdrawal 
symptoms. Drugs that produce dependence often also produce tolerance which 
is defined as an individual increasing dose to maintain desired effect. Aspects of 
dependence are observable in drugs of abuse as well as in medications used for 
common medical conditions including hypertension.  
The DSM-IV further defines substance dependence as including features 
of psychological dependence: compulsive, stereotyped behaviors of drug 
seeking, procurement, and use, often at the cost of other social, work, or self-
care obligations. Some drugs of abuse are traditionally thought  to be 
psychologically but not physiologically dependence-forming (e.g. marijuana, 
hallucinogens).(2) 
Substance abuse is defined as the detrimental pursuit and use of drugs of 
abuse despite negative effects on the user’s livelihood, health, personal 
relationships, and overall quality of life. Involvement with the legal system is 
common as is a chaotic and highly risky lifestyle. The detrimental effects of 
substance abuse on society include lost productivity, criminal involvement and 
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the associated law enforcement- and incarceration-related costs, property 
damage, and health care related costs.(3)  
Recent data from the Substance Abuse and Mental Health Services 
Administration indicate that large portions of the population meet criteria for 
substance abuse and dependence and may suffer from the detrimental effects of 
substance abuse: 8.7% of the U.S. population over the age of 12 were classified 
with substance abuse or dependence by DSM-IV criteria with fully 21.5% 
reporting “last month drug use” in the age bracket 12-25 years old.(4) These 
statistics have been relatively stable over the last 3 years. The estimated cost of 
substance abuse on society in dollar estimates is huge: the National Institute on 
Drug Abuse (NIDA) projected $181 billon in costs related to illicit substance 
abuse and $235 billion in costs related to alcohol abuse.(5) Understanding how 
best to treat substance abuse and lower these social and individual costs is thus 
a clear priority. 
 
Biology of Substance Abuse and its Treatments 
 To best understand substance abuse treatment, there are a few essential 
neurobiological points that should be considered. Understanding the ways in 
which drugs of abuse cause such deep-rooted shifts in individuals is of primary 
importance. Dopamine-driven reward pathways are known to be involved in the 
initiation and continuation of substance abuse and dependence. In brief, these 
are the pathways that normally orient us towards life-preserving behaviors (i.e. 
food, relationships).(1) These pathways are differentially over-stimulated with 
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drugs of abuse and the importance of the drug begins to exceed the importance 
of life-sustaining basics.(6) An essential part of substance abuse treatment is 
addressing the re-orientation of these neurobiochemical pathways towards non-
drug rewards. This often takes time and repeated efforts, contributing to high 
“failure” rates when individual treatment episodes are considered in isolation.  
One of the hallmarks of physiologic dependence is an alteration of 
receptor chemistry. As an addictive substance persists in the central nervous 
system of an individual, the receptors to which the substance binds tend to alter 
their density to accommodate the over-stimulated state that prolonged use incites 
and tolerance develops. Invariably, the receptors stimulated by drugs of abuse 
play roles in normal CNS functioning. This often means that to maintain a feeling 
of “normalcy,” a substance dependent individual must maintain a baseline level 
of substance intake. Without this maintenance of drug levels, an addicted 
individual goes through “withdrawal” – a syndrome of symptoms that varies 
between drugs of abuse resulting from a lack of receptor occupancy. These 
alterations contribute to the behavior of drug-seeking as well as the desperation 
that can accompany it. 
Evidence supports treatment of substance use disorders that focuses on 
behavioral and habitual change (through counseling or various kinds of 
psychotherapy) as well as maintaining normal neurochemical levels (may include 
pharmacotherapy with receptor agonists, partial agonists, or antagonists). As 
with other mental illnesses, the evidence supports a combination of the 
medically- and cognitively-oriented therapies.(7) Pharmacological treatments of 
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substance abuse disorders are limited in scope, but several are highly effective. 
The most effective medical treatments are for opioid abuse of which methadone 
and buprenorphine have the most evidential support.(8) Alcohol abuse and 
dependence can be treated with a number of pharmacologic agents. 
Varencycline and nicotine replacement are evidence-based medication-assisted 
therapies for nicotine dependence. Unfortunately, at this time there are no 
evidence-based medication treatments available for other drugs of abuse, 
including cocaine, amphetamines and club drugs.(7) 
 
Pharmacologic Treatment of Opioid Dependence 
 The most extensive body of evidence exists for opioid dependence 
treatment. The two main pharmacologic agents available both act as agonists on 
the same receptors that opioids of abuse act. Methadone has been available in 
the United States since 1947 and methadone maintenance (MMT) to treat opiate 
addition has been in widespread use since the 1970s. In heroin or other opioid 
addiction (e.g., prescription opioids), the addicted individual’s opiate receptors 
down-regulate and in order to maintain normal function, the presence of an 
opiate agonist is required. Methadone is a full mu opioid receptor agonist with 
greater affinity for the receptor than heroin. A maintenance dose ideally provides 
an individual with enough receptor occupancy to function normally without 
symptoms of opiate withdrawal (i.e. agitation, insomnia, nausea, diarrhea). Its 
oral dosing also prevents injection-related risk of disease transmission. 
Methadone can be injected, however, if taken outside of the clinic context.  
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There is a surfeit of evidence supporting the use of methadone in the 
treatment of opioid addiction, (9, 10) but notably, a 2000 JAMA study showed 
that MMT was significantly superior to detox and psychosocial support in terms of 
maintaining clients in treatment and in the longer term (6-12 months), resulted in 
fewer heroin use days.(11) Methadone itself is also relatively cheap. The 
drawbacks of methadone are numerous, however: because it is a partial agonist, 
there is both a danger of overdose and of diversion and abuse associated with it; 
these features require methadone to be distributed in highly regulated settings 
and with federal regulations on its use, both of which are costly measures.  
 Buprenorphine is a mu-opioid partial agonist. It lacks the danger of 
overdose associated with methadone and strong evidence supports its efficacy, 
(7, 12) although in a meta-analysis, methadone was found to have a marginal 
edge in retaining patients in treatment over buprenorphine.(8) Buprenorphine is 
often dispensed as a formulation with naloxone (a mu-opioid antagonist with very 
high receptor affinity, but not bio-available when taken via sublingual route), thus 
fully discouraging intravenous abuse and limiting diversion. Methadone has a 
stronger evidence base as a result of its longer history on the market, but many 
providers are now using  buprenorphine as a first-line treatment option for opioid 
dependence. 
 Of note, clonidine, a drug which increases regulation of adrenergic tone, is 
used to mitigate opioid withdrawal symptoms. Clonidine is not considered a 
method of maintaining an individual and is only used during acute withdrawal. 
Evidence does not support the use of withdrawal as a method of treatment.(7) 
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Pharmacologic Treatment of Alcohol Dependence 
 There are three medications approved by the FDA for the the treatment of 
alcohol dependence: naltrexone,acamprosate, and disulfiram. Naltrexone is a mu 
opioid receptor antagonist and there is evidence to show that it is the most 
effective treatment modality for alcohol use disorders. It is also used in the 
treatment of opioid dependence, but the depot formulation was only approved in 
late 2010 in the United States. Acamprosate is used to treat alcohol abuse as a 
craving-reduction support, but studies suggest that it is only useful in the most 
motivated patients.(7) The exact mechanism of action of acamprosate is unclear, 
but is thought to relate to glutamine modulation. Disulfiram blocks an enzyme key 
to the metabolism of ethanol metabolites, resulting in severe symptoms if an 
individual taking the medication consumes ethanol. Disulfiram, again, has been 
found to be effective mostly for individuals who have high levels of motivation to 
quit drinking. 
 
Non-pharmacologic Treatment of Substance and Alcohol Use Disorders 
 There are a number of non-pharmacologic means of treatment available 
for both substance and alcohol use disorders. Many of these are geared 
generally towards the goal of re-establishing rewards separate from drugs of 
abuse. Alcoholics Anonymous and Narcotics Anonymous are run on self-help 
and support-group models and are very common in the community and in 
correctional settings. The effectiveness of these modalities are difficult to 
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determine in a controlled way given the inability to control frequency of meeting 
participation due to the anonymous nature of the intervention as well as the 
difficulty in controlling the contents of the intervention. Understanding that, some 
counseling-based interventions have good evidential support. Individual 
counseling and case management services have proven to be effective as 
community-based interventions to reduce substance use and recidivism,(13) but 
a standardized, well-defined intervention has not been widely validated. 
Therapeutic communities (highly structured group housing and therapy) are the 
only intervention with solid evidence to support its effectiveness in the 
incarcerated population.(14) However, its effects are short-lived in those who 
only undergo treatment in the prison milieu and individuals clearly require further 
community-based treatment for prolonged treatment success to occur.(15)  
 
Goals of Substance Abuse Treatment  
The goals of substance abuse treatment are several-fold. The maintenance of 
sobriety is a main goal, with its hopefully accompanying return to more optimal 
living circumstances. The idea of reducing harm to users (be it sexual risk, 
injection-related risk, etc) and reducing criminal involvement are also important 
endpoints of treatment. Opioid agonist treatments have been proven to achieve 
these goals well for opoiod abusing individuals. One important benefit of opioid 
agonist treatments is that they reduce injection and thus the health risks 
associated with it (HCV, HIV transmission, abscesses, etc).(7, 16) Outpatient 
treatment with opioid agonists reduces law infractions and incarcerations, 
	   	   	  
	   10	  
suggesting fewer substance-use-associated risks taken.(17) Also of note, studies 
have shown that the primary cause of death after release from prison is drug 
overdose(18, 19) – harm that is abrogated by bridging to appropriate, effective 
treatment. 
 
Incarceration 
 The so-called “War on Drugs,” starting in the 1980s, was a nationwide 
attempt to curb substance abuse by increasing penalties on those who use illicit 
drugs. The ensuing implementation of numerous laws and judicial standards 
resulted in a precipitous growth of the criminal justice population.  By 2005, 7.1 
million people were under some form of correctional supervision(1), with 1/100 
Americans behind bars in either prison or jail.(20) From 1980 to 1999, this 
reflects an increase of nearly 240%.(21) Sadly, but not surprisingly, the 
incarcerated population skews strongly towards young men, as does substance 
abuse and dependence  (1 in every 30 men in the age bracket 20-34 years of 
age are incarcerated). Among those young men, Black men are 
disproportionately represented (1 in every 9 Black men aged 20-34 is in 
prison).(20)  
It is generally accepted that an increase in drug arrests and tightening of 
minimum sentencing requirements nationwide has been the major driving force in 
the recent burgeoning of the correctional population in the United States.(22) 
Importantly, substance abuse rates in this period have been constant (per 
SAMHSA numbers) while substance abuse-related incarcerations have been on 
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the steep rise.(23) In 1986, only 9% of state prisoners were incarcerated for drug 
law violations.(24) Over the following years, these aggregated national numbers 
increased to nearly 25%.(25) This national growth was more pronounced in some 
states as some states ramped up the proportion of offenders incarcerated for 
drug-related charges tenfold over the period from 1980-1998.(26) The New York 
State Department of Criminal Justice reports the number of arrests for drug-
related crimes (led by possession) sharply increasing after the year 1996.(27) 
Numbers from California reflect a similar timeline with an arrest and incarceration 
profile increasingly laden with drug offenders.(23, 28)  
 This increase in arrests has concentrated a large number of individuals with 
substance use disorders in our nation’s correctional agencies. 2002 self-report 
statistics from the Bureau of Justice Statistics indicate that 53% of inmates were 
abusing or dependent on substances at the time of their arrest and 68% of 
inmates were abusing or dependent on either drugs or alcohol or both.(29) Urine 
drug test estimates from the same time period suggest that 67% of male and 
68% of female arrestees tested positive for drugs (23% tested positive for more 
than one substance).(30) The correctional health care system was woefully 
unprepared for this influx, and rigorous, evidence-based treatment has not been 
the standard.(31) 
Clearly then, the main method of dealing with the issue of substance 
abuse is simply to incarcerate those who use drugs. In a 2002 paper, Hammett, 
et al report data that indicates a rate of 0.38 arrests per year per drug user in a 
large, multi-city United States data set.(32) This high rate of incarceration is 
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reflected again in statistics on re-arrest: 70% of individuals in prison with 
substance abuse or dependence problems had a prior sentence and 47% of the 
same population had 3 or more prior imprisonments.(29) Many of these re-
incarcerations occur for drug use-related violations of parole terms.(25) 
This tendency towards re-incarceration is due to the fact that offenders 
with substance use disorders tend to have high rates of relapse to addiction, 
overdose after release, and high levels of HIV risk, and crime.(15) Many 
releasees return to social circumstances not unlike those they left before 
incarceration and face the same challenges and situations that contributed to 
their incarceration in the first place. (13, 33) There is strong neurobiological 
evidence indicating that many of these situations involve cues that are tightly knit 
in the brains of offenders with substance use disorders and all of the behaviors 
associated with it. (6, 34) Additionally, relapse is highly likely once the 
neurobiological shift to addiction has occurred. (35) In the absence of treatment, 
incarcerating individuals with substance use disorders is thus the equivalent of a 
revolving door - an expensive one. 
Considering the current economic climate, cost to society is an important 
consideration in all public policy decisions and is an important piece of the 
argument for substance abuse treatment in corrections. In 2008, United States 
governments (local, state, and federal) spent roughly $75 billion on 
corrections.(36) An example of this high cost of incarceration can be seen in the 
case of California: in 2004, each new incarceration cost the state an average of 
$30,929.(28) Moreover, 73% of drug-related and 73% of property crime-related 
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offenders were found to be dependent on or abusing drugs at the time of their 
crime,(29) confirming the role of substance abuse in property crime, a significant 
social cost. Treatment that reduces the burden of substance abuse can thus 
result in lower criminality as well as lower rates of risky behavior, reducing the 
burden of crime on society as well as the burden of disease on individuals and 
society alike. Considering these costs as comparable social costs, various cost-
benefit analyses show methadone(3, 37, 38) to be a cost-effective treatment 
measure. Several cost-effectiveness studies have also shown in-prison treatment 
that bridges to community-based treatment to be cost-effective, as well.(21, 39)  
 
Substance Abuse Treatment in Corrections: Current State of the Evidence 
Taken together, the above evidence points strongly to the need for 
treatment of substance and alcohol use disorders in correctional settings for, 
“prison may provide the only opportunity that a marginalized population has to 
engage with treatment services.”(40) At this nexus of social problem and public 
policy lies a burden of substance abuse on individuals suffering from such 
disorders, the burden of crime and lost productivity on society, and a burden on 
government finances wrought by high usage of incarceration alone as a policy for 
dealing with substance abuse. Evidence indicates that there is a clear role for 
including substance abuse treatment in corrections. This inclusion can be likened 
to “case finding” in infectious disease outbreaks and “targeted intervention” in 
many public health endeavors. 
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Prisons and jails have been a difficult place to encourage treatment of 
drug and alcohol use because of an emphasis on security and punishment over 
rehabilitation and support.(41) Historically, this has been the case for all of health 
care in prisons and jails. International agreements on prisoners’ rights have 
attempted to counteract this by arguing that, from a human rights perspective, 
the punishment of confinement is punishment enough; restricting health care 
access and inflicting subhuman treatment on prisoners is a violation of their 
inherent rights.(42) 
Substance abuse treatment in the correctional context has been studied 
and there is an increasingly strong body of evidence in the field. There are 
several secondary questions that arise around this topic: can someone be forced 
to change? Can prisoners be successfully transitioned from in-prison treatment to 
out-of-prison treatment? The issue of whether coerced or incentivized treatment 
works is a question that has been explored at length. While having treatment 
program clients who are ready and willing to change their substance habits 
appears to result in more optimal outcomes(43, 44), coercing engagement with 
treatment has been shown to be an effective means for reducing substance use 
behaviors.(45) This evidence contradicts the conventional wisdom commonly 
held by those in the substance abuse treatment field that individuals who are 
forced into treatment will resist it and thus render treatment worthless, or that 
they will disrupt the treatment milieu and destroy its effectiveness for other 
clients. This data provides a substantial foundation for the idea of placement of 
treatment into such a strongly coercive environment as a prison or jail. 
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Understanding that treatment in coercive environments can work and that 
the evidence in community-based treatment shows definitively that medication-
assisted therapy (MAT) is the treatment of choice, several well-designed studies 
have shown the effectiveness of in-prison methadone maintenance therapy in 
reducing re-arrest, post-release mortality, increasing adherence to community-
based treatment after release, and reduction in post-release drug use. Generally, 
studies support the use of opioid agonist therapy in correctional populations and 
find that, with a sufficiently high dose of medication, retention in treatment is quite 
good.(46)  
A 1992 study performed at Riker’s Island in New York, examined 
enrollment and retention in MMT after a jail term that included either induction 
into or continuation of MMT after booking. At 6-month follow-up, 27% of those 
who received MMT in jail were retained in community MMT treatment, while only 
7% of jail-detoxed controls were retained. Significant positive effects on post-
release criminality and substance use were associated with in-jail MMT.(47) 
In 2005, Kinlock, et al published a study in a cohort of prisoners that 
replicated these results for a prison population. They showed clearly that pre-
release maintenance therapy initiation was associated with entry into treatment in 
the community.(15)  Kinlock’s group then performed a prospective study of in-jail 
MMT in Baltimore, MD and subsequently performed 1-month and 1-year follow-
ups with follow-up supporting a combination of counseling/case management 
and opioid replacement therapy. (48, 49)  
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Dolan, et al performed a more rigorous follow-up four years after their in-
prison MMT trial. Most significantly, releasees who were retained in MMT 
treatment for longer than 8 months had a lower risk of re-incarceration by an 
adjusted hazard ratio of 0.3 (0.2 – 0.5, p < 0.001). They also found that 
individuals who stayed in treatment longer were less likely to drop out of 
treatment as time went on. This may indicate bias in the population retained in 
treatment, or this may indicate a cumulative effect of treatment. They found at 
follow-up that all deaths (17 deaths out of 382 total participants) occurred in the 
out-of-treatment part of the cohort, suggesting a protective effect of MMT.(50) 
A very recent study examined the harm reduction effects of opioid 
substitution agonist therapy in prisons. This research suggests that OST in 
prisons reduces these risky behaviors while in prison, as it has been shown to 
outside of prison.(16) 
With the effects of specific MAT interventions in mind, there’s also 
evidence that just being observed by a program positively affects drug-related 
criminal outcomes. While under the supervision of a day reporting center, 
arrestees sentenced to complete a diversion program had fewer arrests for drugs 
while under supervision than those who were not assigned to complete the 
supervisory program. The effect was seen regardless of program content. (51) 
 
Politics and Substance Abuse Treatment in the Correctional System 
Despite the large amount of evidence to support initiation of rigorous, 
extensive substance abuse treatment programming in the correctional setting, 
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attempts by state and local governments to take a different tack on substance 
abuse have thus far been too small and too short-lived. Several notable policy 
interventions have been undertaken in states like Arizona (Proposition 200), New 
York (Riker’s Island’s KEEP program), and California (Proposition 36). In the 
interest of highlighting the central role of politics in the question of how to deal 
with substance abuse and dependence in the correctional system, a brief 
discussion of California’s Proposition 36 will follow.  
California’s Proposition 36 (The Substance Abuse and Crime Prevention 
Act) was an alternative to incarceration for first- and second-time offenders that 
sent offenders to various community-based treatment programs and amended 
parole-violation laws to mandate community treatment, not in-prison, sentencing. 
Initially, the program was hobbled by California’s budget crisis. Although the 
legislation included provisions that promised to prevent drawing funds away from 
other state-funded substance abuse treatment efforts, Governor Gray Davis did 
exactly that in the face of worsening budget crisis.(52) This shifting of programs 
was made especially visible in a 2007 study by Hser, et al noting clear 
displacement of previously “voluntary” clients out of the substance abuse care 
system by new clients mandated to treatment.(53) Of note, Governor Davis 
opposed the Proposition and it was widely speculated that this re-shuffling of the 
state substance abuse treatment budget was a thinly-veiled attack on the 
Proposition – without the other substance abuse treatment programming funded 
by the state, offenders sentenced under Proposition 36 faced limited numbers of 
program slots and prior offenders who were in treatment were bumped from 
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treatment. Adding to this fiscal opposition from the governor’s office was political 
opposition from California’s drug court judges, district judges correctional officers’ 
unions, and District Attorneys.(54) 
 Thus, the program faced difficulty in enforcing engagement with treatment 
– a full 25% of those sentenced to mandatory treatment failed to enroll in 
treatment and not 50% of those who enrolled completed treatment.(55, 56) This 
failure to enroll in and complete treatment is likely a result of an attempt at 
increasing the number of individuals receiving treatment while simultaneously 
maintaining, or even decreasing, available treatment slots – the result of an 
unsympathetic governor and budget. 
Even in the face of political interference, a significant economic impact 
was realized under Proposition 36: for every dollar spent, $2.50 in value was 
returned to the taxpayers. This value increased to $4 in value for every $1 spent 
when cost-benefit analysis was limited to those who completed treatment.(56) 
Years after its implementation, the courts extended funding on an annual basis 
for several years due to the significant benefits that had been realized. 
The example of California’s Proposition 36 thus serves as an example of 
the influential role of government and politics on substance abuse treatment 
programming and its interface with the criminal justice system and the politically 
popular “War on Drugs.” The role of an evaluation in this field thus must take into 
account the possibility that politics may be playing a role in treatment structures 
and must evaluate that role, if possible. Socially impactful programming should 
be large-scale and comprehensive and thus must rely on large budgets – 
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frequently state budgets. They must also be well integrated within a correctional 
system – a state agency. Thus, the political lessons learned from a case like CA 
Prop 36 are essential when working in or evaluating the field of substance abuse 
for offenders. 
 When the United States is considered alongside other developed nations, 
the dearth of evidence-based substance abuse treatment and harm reduction in 
our correctional system becomes comparatively more obvious. Internationally, 
MMT has been made available in many prison systems, but the United States 
continues to provide little to no access to this evidence-based therapy.(49) 
Canadian studies have shown efficacy of institutional MMT programming in 
reducing criminality and drug use.(57) After this study and a lawsuit by a 
prisoner, Canada expanded its in-prison methadone maintenance access in 
2002.(58) Australia made MMT available to inmates in the 1990s and the positive 
effects of treatment implementation included a reduction in in-prison injection of 
drugs(59), and less drug use after release. Germany made clean syringes 
available to inmates in several prisons in 2000 and saw a reduction of in-prison 
needle sharing as a result, but the program was short-lived, caving under political 
pressure.(60) 
All of this evidence and expert opinion should suggest that drug abuse 
treatment would be more widely implemented in criminal justice settings. 
However, evidence-based practice for substance abuse treatment is only partially 
implemented.(61) A recent survey of methadone and buprenorphine provision in 
U.S. prisons showed widespread reports that methadone was made available to 
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inmates in 55% of state prison agencies. More than half of these only provided 
methadone to pregnant women or as pain medication, however, and few offer 
MMT. Even fewer offer buprenorphine (14%) in any capacity. Only 45% of 
agencies confirmed referring any releasees to community-based MMT 
treatment.(62) There are obstacles to advancing MAT usage in the correctional 
setting, but were not defined by this study.  
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Statement of Purpose and Hypothesis 
 
The purpose of this study is to explore the factors associated with the 
implementation of various kinds of substance abuse treatment, with a special 
focus on MAT, to fill an important gap in knowledge in an effort to direct efforts at 
implementing evidence-based practice in correctional substance abuse 
treatment.  
We hypothesize that funding will be ranked by respondents as a major 
obstacle to substance abuse programming, past and future. We hypothesize that 
funding will also be the most important factor contributing to willingness to 
consider more robust substance abuse treatment programming. We further 
hypothesize that in a multivariate model, factors including geographic location, 
budget, knowledge and attitudes about MAT, facility size, overcrowding, and 
institutional pressures will be noted as significant covariates of MAT-based 
treatment implementation. 
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Methods 
 
Population and Data Collection 
The survey sample was drawn from a previously identified national sample 
of prisons, jails, and community corrections units identified through a 
randomization protocol designed during a prior large-scale national survey of 
correctional facilities (the National Criminal Justice Treatment Practices survey 
[NCJTP], a NIDA-funded project). The NCJTP survey effectively identified 
prisons that implement medication-assisted therapy (MAT) for substance abuse 
treatment (SAT) programming and others that do not.(25) The sample was taken 
from areas of the country with higher drug abuse rates and larger populations, 
both indicators of likely high rates of incarceration for drug abuse-related crimes. 
Their randomization procedure was undertaken with the aim of generating a 
similar broad, national sample, but one that was focused more on drug abuse 
issues than a purely random sample might be. Using a random number 
generator, each facility was assigned a 5- or 6-digit code, with a database of 
each facility’s code kept on a secure encrypted server. For the purposes of 
follow-up, these codes were attached to facility names. Once data collection 
began, the responses were dissociated from their facility names.  
Of note, a single case was discovered from the original randomization that 
constituted a duplication because the county jail and its associated sheriff’s office 
were both included in the sample inadvertently. One of the cases was removed 
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and the response was only weighted once because only one correctional unit 
was represented.  
Survey responses were collected from August 2011 until April 2012. The 
sampling strategy is diagrammed in Figures 1 and 2. We relied on each unit to 
direct the survey to the appropriate respondent within their organization, be they 
a health services administrator, a warden, or other administrator who directs 
substance abuse treatment programming for that unit. The survey packet was 
mailed to each unit in the random sample. Follow-up was conducted using 
telephone and e-mail contact along with redistribution of survey materials when 
required. 
 
Instrument Design Procedure 
 The survey instrument is available in Appendix A.  The mail-based survey 
instrument used in this study was designed in a multi-phase fashion.1 First, an 
extensive search of the related literature was done to ascertain the existence of 
other surveys in the field that focus particularly on the opinions of administrators 
within the correctional system. Though the literature on substance abuse in 
correctional health care is relatively thin, several examples of previously 
executed surveys were found. (25, 63-65) To gain an understanding of the 
current standards of practice, published standards were studied.(66, 67) These 
were studied along with the defining texts on the subject(68-70) and a draft 
instrument was designed, drawing questions and frameworks from existing work. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Note:	  The student author was lead instrument designer, was trained to lead and ran focus groups, 
managed contacts with collaborators, submitted protocols and forms to the Yale School of Medicine HIC, 
managed survey response and follow-up, and performed data entry and analysis.	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The instrument was designed to focus on areas of organizational structure 
identified in previous work. (25, 61, 71) Particularly, funding, overcrowding, and 
attitudes scales regarding past, present, and future barriers were included. Other 
data on staffing change (as a measure of organizational instability) and 
methadone knowledge and attitudes (adapted from McMillan, et al(72)). 
Questions regarding particular numbers (i.e. populations, budgets) were 
standardized by requesting that facilities report their FY 2009-10 numbers for 
those categories. 
In accordance with the recommendations of the survey design texts 
studied, the draft was presented to a focus group of administrators as well as 
treatment staff at the Connecticut Department of Correction. This group was 
made up of individuals who hold positions that mirror those of our target 
respondent population. The feedback from this session was integrated into the 
second draft of the instrument, which was subsequently distributed to a group of 
experts in the field for a second round of feedback. Again, comments and 
criticism were integrated into a third draft of the instrument, which was then 
presented to the Human Investigation Committee at the Yale School of Medicine 
where it was approved, along with accompanying documentation (anonymous-
style informed consent form and cover letter). 
While designing the instrument, we also considered work in the field of 
survey response rate and organizational characteristics that might affect it. 
Historically, surveys of organizations have poorer response rates than surveys of 
individuals (rates between 30 and 65% response have been reported for 
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organizations versus 70 to 75% in individual surveys) and this may be due to the 
hierarchical, bureaucratic nature of organizations and the ability of individuals 
within them to pass a task such as a survey off as “not my job.”(73) In order to 
combat this tendency and increase our study’s relevance to our target group of 
respondents, we explored allying ourselves with the American Correctional 
Association (the professional association for wardens and commissioners of jails 
and prisons). In the end, however, we were unable to facilitate this partnership 
and instead obtained a letter of endorsement from Dr. Faye Taxman, Principal 
Investigator of a number of large criminal justice surveys, with whom many of the 
recipients would be familiar.  
Other barriers to response within organizations include survey length as 
well as restrictions on respondents’ time that make them unable to respond.(74) 
In order to combat the former, with each revision of our drafts, we shortened the 
instrument as much as possible. The latter barrier has been approached by 
ensuring that individuals have organizational support to complete the survey 
within normal business hours, with pay.(25) We were unable to provide this 
incentive, however.Without greater grant support, we were unable to ensure such 
financial or time support, however. 
 
Data Reporting and Measures Employed 
All information was collected by self-report by administrators designated 
by each facility. Data are reported by region and by facility type, but reporting 
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further detail on facility size and location of respondents by state was avoided to 
maintain sufficient anonymity of response.  
For purposes of data analysis, average daily population was parsed into 
quartiles (0-414, 415-1260, 1261-1873, 1874 and above). A measure of 
overcrowding was created by calculating the difference between average daily 
census and stated maximum capacity. The reported budget for FY 2008-09 was 
parsed into quartiles, as well (0-3036500; 3036501-46200000; 46200000-
447000000; 447000001-top). A measure of the comparative weight of substance 
abuse programming within the budget was calculated by taking the ratio of 
monies earmarked specifically for substance abuse treatment programming as a 
percent of the total organizational budget. The inter-quartile split was (0-0.0000; 
0.0000-0.4314; 0.4315-1.7638; 1.7639-top) 
When reporting current program implementation, respondents were asked 
whether programs or treatments were currently available and not whether 
individuals were actually receiving programming. It is assumed that some 
programs may be highly utilized and that some may be underutilized. Program 
flux was measured as any reported increase or decrease in slots or program 
opening or closure in the two years prior to survey completion. Factors 
contributing to increase or decrease were scored on a 0-2 scale in which 0=No 
contributor to change, 1=Minor contributor to change, and 2=Major contributor to 
change. Mean scores were assigned. Only those units indicating that changes in 
programming had occurred were asked to rank factors contributing to program 
change. Openness to future program implementation was asked in light of the 
	   	   	  
	   27	  
respondent imagining that all barriers to opening a kind of treatment 
programming were removed. 
Knowledge and attitudes about methadone was measured using scales 
devised by McMillan and Lapham, 2004.(63). Knowledge scales about 
buprenorphine and naltrexone were not available in the literature and it was 
beyond the scope of this project to design and test new scales. The knowledge 
scale is a 14-point scale and the attitudes scale is a 13-point scale (available in 
Appendix A). For the purpose of logistic regressionstatistical analysis, cutoffs 
were established at the points of central tendency. Both scores were roughly 
normally distributed. Knowledge scores centered around a mean of 9.2 and a 
median of 9.0, so a score of 9 was used as a cutoff. Attitude scores were 
centered around a mean of 8.5 and a median of 8 and 8 was used as a cutoff 
score. 
Regional breakdown of the original sample was done using a map 
generated for prior Department of Justice studies of the criminal justice system. 
 
Data Analysis 
All data was double-entered by hand by the author and double-checked by 
the author. Of note, some data were submitted by state-level agencies and not 
local units because of variations between states in the way that decision making 
regarding substance abuse treatment is made. In several states (CO, DE, FL, MI, 
MN, MO, OK, VA, WA), substance abuse treatment programming is administered 
solely at the state level and units were instructed that it would be inappropriate 
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for them to respond individually. In these cases, background data for several 
measures (inmate population, maximum capacity, funding) were given for the 
entire state agency. These numbers were roughly adjusted by dividing the 
indicator by the total number of units administered by the agency (whether or not 
they were included in our random sample; this data obtained through each official 
state DOC website) to obtain a mean indicator for that state. Each case for those 
states (total 41/124 responses) is thus represented by these adjusted means for 
the indicators mentioned above. 
 Several indicators measured attitudes or perceptions regarding 
contributors to recent program closure and expansion or perceptions regarding 
potential barriers to future treatment programming efforts. These indicators were 
measured by a Likert-scale response attributing the estimated magnitude of 
contribution of the given indicator to the given scenario (e.g. what was the 
possible contribution of new state funding on recently expanded programming). 
The Likert scale responses were assigned point values and a mean score was 
calculated for each. Chi-square analyses were also performed to determine 
whether the empiric differences in score found within contributors were 
measurably valid. 
 Primary outcomes of interest were the implementation of MAT (measured 
as facilities reporting implementation of any MAT - MTD, BPN, or NTX); whether 
a respondent indicated that they had a positive attitude towards implementing 
MAT (measured as a response of “Already Implemented,” “Would Implement,” or 
“Would Consider Implementing” when asked if what their attitude is towards MAT 
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for maintenance, alcohol abuse, or combined with counseling). These two 
outcomes were summed to a final binary outcome of “Would consider or already 
implements MAT.” 
 All statistical analyses were performed using SPSS v.19.0 (IBM, 2010). 
Chi-square and ANOVA were used to analyze differences between reported 
means. Univariate and multivariate logistic regression were used to determine 
the influence of various factors on the noted variables of interest. 
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Results 
 
The final sample was ultimately representative of a national survey of 
criminal justice settings.  Of the 226 sites sent the original survey, the overall 
response rate was 54.9%, with the final sample comprised of 124 diverse 
facilities. Though overall, each region was represented similarly (p = 0.159; see 
Table 1), there was a trend towards increased representation of facilities in the 
Midwest and Southeast. The response rate, however, was significantly lower in 
facilities in the Southwest and Northeast (p<0.001; see Figure 1). Regarding 
facility type, the final sample was similarly distributed with 63% of jails, 53% of 
prisons, and 50.0% of community correctional settings responded to the survey. 
As a portion of the total sample, prisons make up a significant majority (p <= 
0.0010; Table 1), but there was no difference in response rates between facility 
types (p = 0.332; see Figure 2). 
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Figure 1: Sampling Flow Diagram, by Region of U.S. 
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Figure 2: Sampling Flow Diagram, by Facility Type 
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Table 1: Characteristics of Survey Respondents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Legend: 
SAT: Substance Abuse Treatment 
 MAT: Medication-Assisted Therapy 
 AA: Alcoholics Anonymous 
 NA: Narcotics Anonymous 
 
†=ANOVA used to detect difference between mean population sizes
 Total (n) 
 
Chi-square (p) 
Total response rate 54.9% (124)  
Sample Composition (n=124)   
Jails 29.0% (36)  
Prisons 54.8% (68)  
Community Corrections 16.1% (20) <0.001 
   
Northeast 15.4% (19)  
Southeast 26.6% (33)  
Midwest 24.4% (30)  
Northwest 18.7% (23)  
Southwest 15.4% (19) 0.156 
   
Mean Daily Population (All sites) 1817 (SD=3207)  
Jail (n=36) 1602 (SD=1957)  
Prison (n=68) 1660 (SD=1225)  
Community Corrections (n=20) 2592 (SD=7342) <0.05† 
Percent of responding facilities 
operating over stated capacity (n=114) 19.8% (23)  
Median percent of 2009-10 budget 
designated for SAT (n=94) 0.41%  
Any recent increase in budget 
designated for SAT (n=107) 22.4% (24)  
Any recent decrease in budget 
designated for SAT (n=107) 33.6% (36)  
No change in budget designated for 
SAT (n=104) 43.3% (45)  
Currently SAT services (n=124)   
Offers any SAT 82.1% (101)  
Screening  79.8% (99)  
Referral 80.6% (100)  
MAT-Based Programming   
Methadone  15.3% (19)  
 Buprenorphine  2.4% (3)  
Naltrexone  0.8% (1)  
Counseling-Based Programming   
12-step program (AA/NA)  87.9% (109)  
Individual counseling  69.3% (86)  
Group counseling  73.4% (91)  
	  	   34	  
The average daily population census reported by facility type varied widely 
(Table 1). Of the 36 jails responding, the mean reported daily population was 
1,602 (range: 2 to 9,000; SD= 1,957). Variation in the prison population was 
similar with a mean of 1,660 (range: 30 to 5,500; SD=1,225). Community 
corrections units reported a mean population of 2,592 (range: 37 to 32,000; 
SD=7,342). Nearly 20% of facilities reported operating over their stated capacity. 
Budgets ranged widely. The percent of the budget specifically earmarked 
for substance abuse treatment, however, was almost uniformly low, with a 
median of under 1% (0.41%) of the total operating budget set aside for this 
purpose. A majority described recent changes to their substance abuse 
treatment (SAT)-specific budget with 33.6% reporting a recent decrease and 
22.4% reporting a recent increase. 
 
Current Substance Abuse Treatment Practices 
A majority (82.1%) of all facilities reported offering some kind of substance 
abuse treatment (SAT) programming for inmates. In accordance with the 
standards set forth by the National Commission on Correctional Health Care, 
baseline care for inmates who need substance abuse treatment, (66, 67) a 
majority of facilities have systems for screening for and referral to SAT (see 
Table 1). 
More facilities offered counseling-based treatment than MAT. Nearly all 
offer 12-step programming, either Alcoholics Anonymous (AA) or Narcotics 
Anonymous (NA) (n=109; 87.9%), group counseling (n=91; 73.4%), or individual 
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counseling (n=86; 69.3%) while a minority (n=20; 16.1%) of respondent facilities 
offers any MAT. Nineteen (15.3%) offer methadone (MTD), even fewer (n=3; 
2.4%) offer buprenorphine (BPN), and 1 offers naltrexone (NTX). The number of 
individuals receiving MTD in those facilities providing it varies widely (mean = 85, 
SD = 152). Of those who stated they do provide MTD, 82.4% are generally 
satisfied with it. Of note, only 8 of the respondents who indicated that they do not 
provide methadone in their unit noted that they do not have individuals who 
would benefit from MTD treatment; community corrections units were more likely 
to indicate this (p<0.001) but there was no statistical difference between regions 
(p=0.183). 
There is a significant difference in which regions offer any substance 
abuse treatment services (p = 0.065; see Table 2), favoring the Northwest, 
Northeast, and Midwest. MAT, similarly, is disproportionately offered in these 
regions (p < 0.05; see Figure 3).  There is a significant difference in which 
facilities offer any substance abuse treatment (p < 0.01; see Table 3), favoring 
prisons. Jails, however, disproportionately offer MAT (p < 0.001; see Figure 4).  
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Table 2: Availability of and Attitudes About MAT for Substance Abuse Treatment by Geographic Region 
 
 
 
 
*=Significant at p<0.05  
†=Significant at p<0.01 
‡=Significant at p<0.001 
 All Northeast 
(19) 
Southeast 
(33) 
Midwest 
(30) 
Northwest 
(23) 
Southwest 
(19) 
Chi-Square 
Any SA Treatment 
available (n=124) 81.5% (101) 94.4% (17) 90.9% (30) 76.7% (23) 82.6% (19) 63.2% (12) 0.065 
Any MAT currently 
available (n=124) 16.1% (20) 26.3% (5) 3.0% (1) 13.3% (4) 34.8% (8) 10.5% (2) <0.05* 
MMT 15.7% (19) 27.8% (5) 3.0% (1) 13.3% (4) 34.8% (8) 5.3% (1) <0.01† 
BPN 2.3% (3) 0 (0) 0 (0) 3.3% (1) 4.5% (1) 5.3% (1) 0.678 
NTX 0.8% (1) 0 (0) 0 (0) 3.3% (1) 0 (0) 0 (0) 0.559 
Implements or would 
consider 
implementing MAT 
(n=115) 55.7% (64) 58.8% (10) 16.7% (5) 80.0% (24) 70.0% (14) 61.1% (11) <0.001‡ 
If barriers were 
removed, would add 
new SA treatment 
programming (n=116) 93.1% (108) 88.9% (16) 100% (28) 89.7% (26) 95.7% (22) 88.9% (16) 0.428 
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Figure 3: 
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Table 3: Availability of and Attitudes About MAT for Substance Abuse Treatment by Facility Type 
 
 
 
*=Significant at p<0.05  
†=Significant at p<0.01 
‡=Significant at p<0.001 
 All Jail (36) Prison (68) Community 
Corrections 
(20) 
Chi-square 
Any SA treatment 
available (n=124) 81.5% (101) 66.7% (24) 92.5% (62) 75% (15) <0.01† 
Any MAT currently 
available (n=124) 16.1% (20) 38.9% (14) 7.5% (5) 5% (1) <0.001‡ 
MMT 15.4% (19) 36.1% (13) 7.5% (5) 5.0% (1) <0.001‡ 
BPN 2.3% (3) 5.6% (2) 1.6% (1) 0 (0) 0.346 
NTX 0.8% (1) 0 (0) 1.5% (1) 0 (0) 0.658 
Implements or would 
consider implementing 
MAT (n=115) 55.7% (64) 64.5% (20) 51.6% (33) 55.0% (11) 0.491 
If barriers were 
removed, would add 
new SA treatment 
programming (n=116) 93.1% (108) 87.9% (29) 96.8% (61) 90.0% (18) 0.216 
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Figure 4: Current Availability of Any MAT (methadone, buprenorphine, or 
naltrexone) 
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Recent Changes in Programming 
 About 70% of the sample indicated that some change in SA programming 
had occurred in the last 2 years with 53 respondents indicating some increase in 
programming and 35 indicating some decrease in SA programming. The great 
majority of respondents in the Northwest (77.3%) indicated recent program 
decreases (Figure 5) with almost 50% of respondents in the Southwest similarly 
reporting decreases, and a minority of respondents in the Midwest, Northeast, 
and Southeast reporting decreases in programming (p<0.001). The majority of 
respondents in the Southeast (71.9%) and Midwest (55.5%) reported some 
recent increase in SA programming, with roughly a third of respondents from the 
Southwest and Northeast and a minority of respondents from the Northwest 
reporting recent increases (p<0.001; see Figure 6).  
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Figure 5: 
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Figure 6: 
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 When examined by facility type, there was no statistical difference across 
all three types (p=0.305), nor was there a significant difference between groups, 
among those reporting recent decreases in SA programming. An empirically 
greater proportion of community corrections units reported decreases than jails 
or prisons (Figure 7). Prisons were more likely than jails or community 
corrections units to report programming increases (p<0.001; see Figure 8). 
 
Figure 7: Programs Reporting Recent Decrease in Programming, by Facility 
Type 	  	  	  
	  
 
 
 
 
0
12.5
25.0
37.5
50.0
42.1
29.7
22.2
P
er
ce
nt
 r
ep
or
tin
g 
re
ce
nt
 p
ro
gr
am
 d
ec
re
as
e
Jail (n=35) Prison (n=65) Community Corrections (n=19)
p=NS
p=NS
p=NS
	  	   44	  
Figure 8: Programs Reporting Recent Increase in SA Programming, by Facility 
Type 	  	  	  	  
	  
  
 
 
 
 
Respondents who reported programming decreases were asked to rank 
possible contributing factors to program contraction (Figure 9) on a scale of no, 
minor, or major contributor to decrease. Funding cuts were the only factor with an 
aggregate score above 1 (where 1 = “minor contributor to decrease”). Other 
factors such as “leadership dissatisfaction with programming” and “no proof that 
MAT works” were not even considered to be minor contributors to decrease.  
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Figure 9: Factors Contributing to Recent SA Program Contraction (n=35) 
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Respondents who reported program increases were similarly asked to 
rank possible contributors to increase (Figure 10) using a similar scale. “Excess 
need for treatment services” tallied the highest aggregate rank, but “reduction of 
recidivism,” “new support from leadership,” “new federal funding,” and “new state 
funding” were all ranked above a score of 1 (minor contributor to increase). 
 
 
Figure 10: Factors Contributing to Recent SA Program Expansion (n=53) 
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Future Treatment Consideration 
 When asked broadly whether they would consider increasing 
implementation of any SA treatment programming should all barriers to doing so 
be removed, 93.1% of respondents indicated that they would. There was no 
difference between geographic groups or facility types (Tables 2 and 3, pp 35-
36).  
When asked about particular programs (Figure 11), roughly 60% of 
respondents indicated that they would not consider implementing MAT 
programming in the absence of counseling (either for opioid or alcohol abuse) 
and 45% would not consider offering MAT with counseling. In contrast, the great 
majority of respondents already had counseling-based programming in place 
(92.4% reported implementation of 12-step programs, 74.1% reported individual 
counseling and 77.8% group counseling) and few reported unwillingness to 
implement future counseling-based SA programs.
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Figure 11: Current and Future Implementation of SA Programming
0
25
50
75
100
12
-S
tep
 P
ro
gr
am
 (1
18
)
Ind
ivi
du
al 
Co
un
se
lin
g (
11
6)
Gr
ou
p 
Co
un
se
lin
g (
11
7)
M
AT
 fo
r M
ain
ten
an
ce
 (1
16
)
M
AT
 fo
r A
lco
ho
l A
bu
se
 (1
16
)
M
AT
 P
lus
 C
ou
ns
eli
ng
 (1
15
)
61.260.3
45.2
2.62.50.9
28.4
37.1
47
19.7
5.1
25
10.3
2.6
7.8
77.8
92.4
74.1
Counseling Programs                                                        MAT Programs
Already implemented
Equivocal about implementation
Would not consider implementing
P
er
ce
nt
 r
es
p
on
d
in
g
	  	   49	  
When the responses to program-specific questions about future 
implementation were divided by region, the only region in which fewer than half 
of respondents were opposed to implementing MAT alone for opioid dependence 
was the Northwest (35% opposed; see Figure 12) with the Southeast most 
opposed to this option (83.3%). Most regions were less opposed to MAT with 
counseling (23.3%-41.9%; see Figure 13), but the Southeast registered higher 
rates of opposition (83.3%). 
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“Lack of funding” topped the list of perceived barriers to any possible future SA 
treatment programming (Figure 14) as the only barrier with a mean score near 3 
(“Significant barrier”) and a median score of 3. Other barriers ranked between 2 
(“Moderate barrier”) and 1 (“Minor barrier”) were “Lack of physical space” (1.62), 
“Lack of qualified staff” (1.49), “Organizational capacity” (1.41), and “Public 
attitudes” (1.03). 
 
Figure 14: Perceived Barriers to Potential Future SA Treatment Programming 
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Attitudes Towards MAT 
Results from regional and facility-type stratification of the combination 
variable of interest, “Would you consider or do you currently implement MAT?” 
followed similar regional trends. Respondents from the Southeast were 
significantly more likely than those from other regions to indicate that they would 
not be interested in offering or considering MAT programming (p<0.001; Figure 
15). There is no significant difference between facility type in whether 
respondents indicate that their units currently offer, or would consider offering, 
MAT programming (p = 0.491; see Figure 16).  
 Of note, two important variables were found to be collinear with attitude 
scale scores. Facility type was also found to be collinear with attitudes (B=0.41; 
95% CI: 0.21, 0.82; p<0.001). When parsed by facility type, having reported from 
a jail had a significant relationship with attitudes, with a higher score resulting if 
the respondent were reporting from a jail (B=3.17; 95% CI: 1.23, 8.18). Being a 
respondent from a prison or a community corrections unit was not significantly 
associated with attitudes scores. Knowledge scores and attitudes scores were 
also found to be collinear with greater knowledge predicting more positive 
attitudes (B=5.03; 95% CI: 3.35, 6.81; p<0.001). 
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Figure 16: Positive Views on MAT – Percent who implements or would consider 
MAT, by Facility Type (n=123) 
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one type of MAT usually responded that they were unaware of the evidence for 
other kinds of MAT (Table 4). Upon further inspection, lack of knowledge about 
studies negatively influenced respondents’ willingness to consider MAT (Table 
5). 
 
Figure 17: Awareness of Relevant Studies in Selected Areas of SA Treatment 
 
 
 
 
 
0
20
40
60
80
Group counseling Individual counseling MAT for opioid dep. MAT plus counseling 
39
42
1616
42
32
58
77
Shown to work 
Not sure of studies 
Shown not to work 
P
er
ce
nt
 o
f R
es
p
on
d
en
ts
	  	  
57	  
57	  
Table 4: Correlations Between “Unsure” Reponses on Questions About Pertinent 
Studies on SA Treatment Programming 
 
 
*=Significant at p<0.05  
†=Significant at p<0.01 
‡=Significant at p<0.001 
 
 
 
Table 5: Bivariate Correlations Between Respondents Who Are “Unsure of 
Studies in My Population” and “Would Consider Implementation” 
 
 
Would Consider: 
Unsure of 
studies on 
MAT to treat 
withdrawal 
Unsure of 
studies on 
MAT for 
opioid 
dependence 
Unsure of 
studies on 
MAT for 
alcohol 
dependence 
Unsure of 
studies on 
MAT and 
counseling 
MAT to treat 
withdrawal 
-0.383‡ 
n=91 
-0.383‡ 
n=92 
-0.402‡ 
n=92 
-0.459‡ 
n=92 
MAT for opioid 
maintenance 
-0.219* 
n=91 
-0.257 † 
n=92 
-0.227* 
n=92 
-0.303† 
n=92 
MAT for alcohol 
dependence 
-0.178 
n=91 
-0.183 
n=92 
-0.159 
n=92 
-0.212* 
n=92 
MAT and 
Counseling 
-0.217* 
n=91 
-0.232 * 
n=92 
-0.212* 
n=91 
-0.293† 
n=92 
 
*=Significant at p<0.05  
†=Significant at p<0.01 
‡=Significant at p<0.001 
Unsure of Studies 
on: 
MAT for 
treatment of 
withdrawal 
MAT for 
maintenance 
MAT for 
alcohol 
abuse 
MAT plus 
counseling 
MAT for treatment 
of withdrawal 1    
MAT for 
maintenance 
0.957‡ 
n=92 
1 
  
MAT for alcohol 
abuse 
0.916‡ 
n=92 
0.892‡ 
n=93 
1 
 
MAT plus 
counseling 
0.822‡ 
n=92 
0.805‡ 
n=93 
0.829‡ 
n=93 
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Regression Analysis of Factors Contributing to Implementation of MAT 
Univariate logistic regression was performed to measure the fit of a 
number of covariates included in the original model (region, facility type, unit 
census, budget, overcrowding, organizational flux, knowledge, and attitudes; see 
Table 6). Two factors were significantly predictive of any MAT implementation 
(MTD, BPN, or NTX): Facility type (B=0.16; 95% CI: 0.06, 0.44) with jails more 
likely to implement MAT and; Attitudes score (B=10.21; 95% CI: 2.14, 48.72), for 
which a higher attitudes score was predictive of MAT implementation. An 
additional factor was nearly significantly associated (p=0.06): Percent of budget 
dedicated to SA treatment (B=0.63; 95% CI: 0.39, 1.04). In multivariate 
regression including these covariates as well as knowledge score (Table 6b), 
only attitudes score remained significantly predictive of MAT implementation 
(B=6.12; 95% CI: 1.05, 35.73) 
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Table 6: Covariates Contributing to Implementation or Positive Views on 
Implementing MAT Programming 
 
Covariate Implements MAT 
β (95% CI) 
Implements or willing to 
consider implementing 
MAT 
β (95% CI) 
Region (n=115) 0.50 
(0.72,1.69) 
1.41 
(1.04,1.90)* 
Facility type (n=115) 0.16 
(0.06,0.44) 
0.79 
(0.45,1.39) 
Average daily census 
(n=111) 
1.16 
(0.74,1.81) 
-0.93 
(0.66,1.30) 
Overcrowded (n=107) 1.21 
(0.36,4.10) 
0.97 
(0.38,2.49) 
Total budget size (n=97) 1.08 
(0.69,1.69) 
0.64 
(0.44,0.92)* 
Percent of budget 
earmarked for SA treatment 
(n=89) 
0.63 
(0.39,1.04) 
1.238 
(0.86,1.78) 
Any recent increase in SA 
treatment budget 
0.66 
(0.17,2.53) 
5.71 
(1.78,18.33) 
Any recent decrease in SA 
treatment budget 
0.10 
(0.01,0.76) 
0.23 
(0.10,0.56) 
Any increase in 
administrative staff (n=92) 
0.00 0.97 
(0.08,11.1) 
Any decrease in 
administrative staff (n=92) 
0.39 
(0.10,1.49) 
1.18 
(0.47,2.95) 
Any increase in SA 
treatment staff (n=92) 
0.00 WEIRD RESULT 
(8.74000000; 0.00,no 
upper limit 
Any decrease in SA 
treatment staff (n=92) 
0.28 
(0.04,2.33) 
2.07 
(0.77,5.56) 
Any increase in correctional 
officer staff (n=93) 
2.03 
(0.36,11.44) 
3.21 
(0.37,27.95) 
Any decrease in 
correctional officer staff 
(n=93) 
0.83 
(0.29,2.40) 0.60 
(0.25,1.42) 
Knowledge score (n=86)	   1.43 
(1.07,1.9) 
1.18 
(0.98,1.42) 
Attitudes score (n=86)	   1.79 
(1.26,2.53) 
1.27 
(1.05,1.54)* (p=0.015) 
Knowledge score (cutoffs) 
(n=86)	   3.25 (0.85,12.43) 0.86 (0.34,2.19) 
Attitudes score 
(cutoffs)(n=86)	   10.21 (2.14,48.72) 3.08 (1.17,8.11)* 
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Table 6b: Multivariate Analysis 
 
 
Regression Analysis of Factors Contributing to Implementation or Willingness to 
Implement MAT Treatment Programming 
 The same group of covariates was also tested for fit with MAT 
implementation with the addition of willingness to consider MAT implementation 
(region, facility type, unit census, budget, overcrowding, organizational flux, 
knowledge, and attitudes). Three factors were significant on univariate 
Covariate Implements MAT 
β (95% CI) 
Implements or willing to 
consider implementing MAT 
β (95% CI) 
REF 1.00 1.00 
Region 
 1.18 
(0.73,1.91) 
NS 
Facility Type 
0.36 
(0.10,1.31) 
NS  
Budget size 
 1.01 
(0.50,2.02) 
NS 
Percent of budget 
earmarked for SA 
treatment 
0.61 
(0.25,1.47) 
NS  
Recent increase in SA 
treatment budget 
4.24 
(0.30,59.30) 
NS 
5.30 
(1.27,22.06) 
p<0.05 
Recent decrease in SA 
treatment budget 
0.76 
(0.04,14.46) 
NS  
Knowledge score 
 0.50 
(0.10,2.59) 
NS 
Attitudes score 
8.34 
(1.36,51.03) 
p<0.05 
5.97 
(1.48,24.06) 
p<0.05 
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regression: region (B=1.41; 95% CI: 1.04, 1.90); total budget size (B=0.64; 95% 
CI: 0.44, 0.92); and attitudes score (B=1.27; 95% CI: 1.05, 1.54). 
 Five factors were placed into the final multivariate model: region, facility 
type, budget size, knowledge score, and attitudes score. On multivariate logistic 
regression, only the attitudes score was significantly predictive of likely 
implementation or willingness to implement MAT treatment programming 
(B=4.93; 95% CI: 1.25, 19.52). 
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Discussion 
 
 This study is among the first to examine in detail the availability of MAT in 
the United States correctional setting. Other recent studies have examined the 
availability of counseling-based treatment programming(25, 61), one has 
examined the availability of methadone and buprenorphine in state prisons(62) 
but not the related factors, and one has examined some factors contributing to 
MAT-based programming.(75) Our findings that substance abuse-specific 
funding is an important factor in whether MAT-based programming is 
implemented is unique. Our finding that administrator knowledge and attitudes 
play an important role in whether MAT is available in their system and in whether 
they would consider MAT coincide with Friedmann’s work.(61, 75) The apparent 
interplay of positive attitudes towards methadone with substance-abuse-specific 
funding in administrators’ willingness to consider MAT-based therapy in their 
units is also a unique and compelling finding. 
 
Lack of MAT Availability 
Our study reports the availability of programming, not the utilization of 
programs. Other studies have focused more on actual utilization and this work 
indicates that relatively few inmates are receiving treatment of any kind (22, 25), 
and even if significant advances were made in the intervening 5 years between 
these studies, the broad trend would still likely hold true. 
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With respect to MAT-based SAT programming in particular, our study 
revealed 20% implementation of any MAT (MTD, BPN, or NTX) and 15.7% of 
respondents indicating that they provide methadone, results which are discordant 
with the two past studies to look at MAT availability in the correctional setting. 
The study by Nunn, et al reported that 55% of state prison administrators stated 
that methadone was provided in their facilities. Over half of these facilities further 
indicated that methadone was solely used for acute withdrawal management, as 
pain medication, or for pregnant women, a ratio somewhat closer to that which 
was observed in this study. Our results, obtained largely from units instead of 
state agencies and from a wider array of facility types, indicate that methadone is 
far scarcer than what is indicated by Nunn, et al.(62) This may indicate a gap 
between stated policy on MAT availability and actual practice “on the ground.” 
Additionally, this study only had one respondent per state and response bias may 
have influenced the findings as respondents were easily identifiable. 
Friedmann, et al also noted a much higher use rate of MAT (83% in both 
jails and prisons) for opioid withdrawal.(75) However, this definition included 
clonidine to alleviate opioid withdrawal symptoms. When focusing more 
particularly on opioid replacements (MTD or BPN), the study by Friedmann found 
that roughly 50% of jails and prisons reported implementing methadone or 
buprenorphine and that fully 25% of each reported policies of continuing opioid 
replacement therapy if an individual entered their facility in a treatment program – 
about twice the rate of MAT for opioid-related therapy as found in our study. One 
mitigating factor is that Friedmann’s study population was drawn from a select 
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group of correctional agencies using the CJ-DATS study group. This group tends 
to be associated with academic centers and is likely to be more oriented to 
evidence-based practice than the broad, national sample that we drew from. This 
population is also more skewed to the Northeast and may not include units from 
less MAT-friendly parts of the country. Of note, the Friedmann study did not 
comment on the geographic origin of their respondents. 
Neither these two studies nor our study indicates adequate MAT 
implementation, however. Given the longstanding and desperate need for 
measures that reduce the population of imprisoned drug users, the lethal danger 
of overdose in the population of drug-dependent releasees(18), and the cost to 
society of untreated chemical dependency, the continued lack of availability of 
this evidence-based treatment is disappointing. The trend towards a lack of EBP 
in correctional settings is, unfortunately, common. Friedmann, et al reported a 
similar lack of evidence-based practice in their 2006 article, which analyzed the 
National Criminal Justice Treatment Protocol (NCJTP) database searching for 
EBP. They found that corrections-based drug abuse programming, when in 
place, was on average <60% evidence-based practice.  
There is reason to believe that concerted efforts geared towards systemic 
change can alter the constellation of services available to inmates, however. 
Mumola reported that between 1997 and 2004, the number of inmates receiving 
any drug treatment in federal prisons had nearly doubled.(76) During this period, 
a call to action had been taken up and pressure on correctional agencies to 
provide some form of treatment had begun to coalesce. It is reasonable to hope, 
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then, that efforts at raising the call for increased uptake of evidence-based 
treatment in the correctional system will result in substantive change, albeit 
perhaps slowly. 
 
Bias Towards Counseling-Based Treatment Programming 
 In this study, the correctional system’s tendency to prefer counseling-
based treatments is evident. While these do constitute some of the EBP that 
have been studied in correctional populations, there continues to be resistance to 
MAT-based programming, despite solid evidence for its use. Conversely, rates of 
implementation of counseling-based programs are high and the resistance to 
implementing future counseling-based treatment is low nationally and across 
facility types. Studies by Friedmann and Taxman, both using the NCJTP 
instrument, and this author’s literature review for this work indicate that the 
correctional literature largely focuses on 12-step programming, Therapeutic 
Communities, and case management for SA treatment.(25, 61) While evidence 
does support the effectiveness of some of these counseling-based treatments in 
correctional systems (though not 12-step programming, the most commonly 
available “treatment”), community-based studies of SA treatment consistently 
show that MAT is superior across a range of treatment outcomes. This generally 
indicates a trend that is seen further in this study that there is currently greater 
favor given to counseling-based programming and a lack of willingness to even 
consider MAT. This trend may be visible when respondents were asked to 
consider the possibility of implementing MAT alone or with counseling. 
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Respondents were more likely to be willing to consider MAT with accompanying 
counseling than MAT alone. Whether this is because of an understanding of the 
evidence in the literature supporting MAT with counseling over MAT alone was 
not possible to determine. 
  
Differences Across Facility Types 
Interestingly, the use of MAT in corrections appears to be partially 
explained by the kind of facility within the correctional system in which treatment 
is being provided. Generally speaking, jails hold individuals for a shorter period of 
time (anywhere from hours to weeks or a few months) than prisons (usually for 
sentences on the order of many months to years) and are the location of the 
initial contact that an offender has with the system. In the jail setting, then, there 
is more likelihood that an individual would go through withdrawal or be dropped 
from their maintenance therapy (if they are enrolled in an opioid replacement 
therapy program) compared to the prison setting. Jail administrators thus see a 
unique pressure to provide MAT that prisons lack.  
In prison, individuals have often been “detoxed” at the jail level before 
sentencing, and thus there is very little perceived need to provide maintenance 
therapy. Community corrections units often receive individuals once they have 
been released on parole from a prison sentence and so in this regard, they see 
somewhat of a similar population as that seen in prisons. Community corrections 
agencies also monitor those on probation, an alternative to prison, but in the 
absence of continuation of methadone therapy in the local jail, individuals 
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released to probation are also often not maintained on MAT, having been 
detoxed in jail. This is borne out in our results in which a most of the respondents 
who indicated that they do not have individuals who would benefit from MAT 
were community corrections respondents. 
Thus, jails are the only units that receive individuals who are either 
currently physically addicted to a substance or maintained on a dose of MTD or 
BPN. This is borne out in the distribution of MAT and in the univariate analysis. 
The fact that attitudes towards methadone are higher amongst those 
administrators responding from a jail may indicate that more familiarity with MAT 
results in more positive feelings about its potential usefulness. Similar to the bias 
towards counseling-based treatment in the majority of the sample, these results 
point to the fact that as an institution becomes familiar with a mode of treatment, 
their comfort increases and their attitudes become more positive.  
Friedmann, et al(75) and Taxman(25) did find similar absence of MAT in 
community corrections environments. Friedmann found greater presence of MAT 
in prisons than our study found, however, in a proportion equaling that of jails. 
They also did find that prison-based respondents indicate that they prefer drug-
free treatment more than jail-based respondents, which tends to be in keeping 
with our findings that jails appear more open to MAT-based programming.(75)  
Of note, the same study by Friedmann found that there was no difference 
across facility types regarding openness to considering MAT-based 
programming. Our study found a similarly common level of openness to MAT 
across facility types, indicating that while the institutional pressures on each kind 
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of facility and the current distribution appears different, all correctional facility 
administrators view some role for MAT-based programming. This is an easily-
missed but important result from our study.  
 
Regional Differences 
 One particularly interesting trend in the data is regional variation that runs 
throughout. This is first noticeable in the response rate from each region, which 
strongly favors the Midwest. The Southeast was less likely to provide any MAT, 
while the Northwest and Northeast, on the other hand, were both more likely to 
provide MAT than other regions. The 2009 survey by Nunn, et al notes a similar 
regional difference in methadone and buprenorphine availability.(62) Additionally, 
a majority of respondents in all other regions other than the Southeast were 
willing to consider providing MAT if they didn’t already provide it. 
When willingness to provide MAT was parsed by particular program, it 
appeared that respondents in the Northwest were more willing to provide MAT for 
opioid maintenance therapy without counseling, but that this difference lessened 
if counseling were added to the programming (perhaps further evidence that 
respondents are more comfortable with counseling than with MAT alone). 
Respondents from the Southeast, however, stated opposition to any MAT-based 
treatment programming. This trend is borne out into the univariate regression 
analysis in which region is a significant, albeit minor, predictor of positive stance 
towards MAT (either current or potential future implementation). Interestingly, 
Southeastern respondents also indicated the highest percentage of those 
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reporting recent program expansion. Of note, neither Taxman nor Friedmann’s 
work stratified responses by region. 
The strength of this pattern may point to the effects of a regional 
difference in drug use patterns that drives local treatment patterns. Some areas 
of the country have lower heroin and prescription opioid addiction rates 
compared to other drugs of abuse (cocaine, methamphetamine, alcohol, etc). 
However, very few respondents indicated that their facilities do not have 
individuals who would benefit from MAT and these responses were evenly 
spread across regions. Thus, this is an unlikely explanation for the variation 
seen. 
Simply by offering a treatment, institutions may become more comfortable 
with it and be more open to using it in the future. These regional patterns may 
indicate that respondents in the Southeast have not reached the same level of 
comfort with or knowledge about MAT simply because of the fact that this 
treatment is not used in this region. A number of respondents noted on the 
returned survey forms that they do not provide methadone simply because it has 
not been a part of programming in the past. This trend may change if education 
or pilot programs are implemented locally that alter local levels of awareness 
about how MAT works. 
This regional trend may also be reflected in the regional skew seen in the 
landmark studies and policy interventions utilizing MAT in the correctional setting. 
The studies by Kinlock, et al were performed in Baltimore, Magura’s work was 
done at Riker’s Island in New York, and Dolan’s work was done in Australia. 
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California, Washington, New York and Arizona are the states most notable for 
taking progressive stances towards drug abuse treatment in correctional 
settings.(15, 49, 77, 78) The Southeast, then, may simply have less exposure to 
MAT as a treatment possibility. Even though region was not found to be a 
significant covariate in multivariate analysis, an understanding of which regions 
of the country are in most need of intervention to encourage evidence-based 
SAT will help those seeking to encourage that change focus their efforts on areas 
with the greatest need. As exposure to MAT increases, knowledge about it and 
attitudes towards it may also change. 
 
Differing Role of Funding 
Our initial hypothesis was that funding would stand as the most significant 
contributor to changes in treatment implementation. Our study was done in the 
context of a massive economic downturn with accompanying budget cuts all 
around the country in state budgets as well as in correctional systems’ substance 
abuse treatment services (including the defunding of Proposition 36 in 
California). (79) These cuts have decimated state-funded SAT programming. In 
the wake of cuts in California, one insider noted, “I think that policy makers now 
understand the cost benefits of treatment, but are trying to cope with a massive 
short term deficit.” (79) 
In keeping with this empiric understanding, in our survey, funding 
availability was reported as the greatest contributor to program closure and 
decrease, and was viewed as the most important potential barrier to future 
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treatment. When respondents who reported program increase were asked to 
rank possible contributors to that increase, funding was less important than 
offender need and equally important as leadership attitudes. This indicates the 
complex nature of funding as a contributor to programming. Empirically, this 
makes sense: if money disappears, a program must close, regardless of how 
much it may be needed; if leadership at an institutional level demands 
programming, available funds may be shifted towards this new priority, thus 
causing expansion. Population pressure on the system, as measured by the 
responses, “excess offenders requiring treatment” and “recidivism reduction,” 
puts pressure on leadership to promote effective ways of reducing inmate 
populations. Substance abuse treatment and diversion are proven methods of 
accomplishing this aim, and likely contribute to the attitudes of leadership 
towards instituting more treatment programming. In this way, funding is a 
necessary ingredient to program implementation, but not the only one. 
 In both univariate and multivariate analysis, size of budget and amount of 
budget allocated to SA treatment were not significantly associated with MAT 
implementation or willingness to implement MAT. Interestingly, SA budget flux 
was predictive of both in univariate analysis: SA budget decrease was predictive 
of current MAT implementation and SA budget increase was predictive of current 
implementation of or willingness to implement MAT. In multivariate analysis, SA 
budget increase remained a significant predictor of MAT implementation and 
willingness to implement MAT, along with respondent attitudes towards MAT. 
This relationship suggests that the above hypothesis is true: with increased 
	  	  
72	  
72	  
funding and positive administrator attitudes, the possibility of implementing MAT 
becomes greater.  
Notably, this relationship doesn’t hold through when looking at the 
influence of SA-specific budget increase on current MAT treatment 
implementation. This is likely due to insufficient response (so few respondents 
had both a recent increase in SA funding and currently provide MAT). It is 
possible also that the level of SA funding currently available is still too low to 
sufficiently encourage MAT implementation, pointing to the need to increase SA-
specific funding, and specifically for evidence-based treatment.  
For as big of a problem as substance abuse is, very little of respondents’ 
budget is set aside specifically for SAT (median fraction dedicated to SAT was 
0.4% of the total budget; Table 1). Empirically, this is likely because correctional 
institutions often place SAT programming within another part of the budget – 
most commonly, it falls under medical or inmate programming. A simple 
intervention to protect SAT programming and to raise its profile within 
correctional institutions may be to create an explicit line of an agency’s budget for 
it. The import of a suggest that this activity of setting aside SA treatment-specific 
funds is vital to contributing to an environment in which administrators feel 
comfortable considering MAT implementation. 
None of the three other recent major surveys covering SAT in the 
correctional setting look at actual funding levels for substance abuse treatment. 
The NCJTP- based studies (Taxman, 2007 and Friedmann, 2006) queries 
respondents’ attitudes towards current funding levels for programming, but does 
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not ask for dollar amounts separate from administrator attitudes. This entangles 
the coexistent possibilities that an administrator may have insufficient funds and 
believe them to be enough (because of a bias against SAT in correctional 
settings) or for an administrator to view comparatively ample funding skeptically. 
By separating these variables, our survey achieves a higher degree of specificity 
with regards to the role of funding. The survey by Nunn, et al did not publish any 
funding-related factors. 
 
Role of Attitudes in MAT Implementation 
Contrary to our hypothesis, the most significant contributor to current MAT 
implementation is respondent attitude towards methadone. This finding is in 
keeping with the general pattern that appears in our data: funding appears to be 
an important factor insofar as it is a necessary ingredient to program existence. 
Once funding is in hand, the preferences and attitudes of the administrators 
allocating the funding then become more important predictors of the shape that 
funding actually takes.  
Scores on the attitudes scale were also found to be collinear with scores 
on the knowledge scale, suggesting this may be the reason knowledge was not 
predictive of MAT implementation in multivariate regression. In Friedmann’s 2006 
study of the implementation of evidence-based practice (EBP) in NCJTP-
surveyed units, it was found that attitudes towards EBP were the best predictor of 
their implementation. This group also found that knowledge and attitudes trended 
together as independent positive predictors of EBP implementation. 
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Role of Knowledge 
 Knowledge about MAT and awareness of the studies around MAT in 
corrections has a significant impact on whether respondents would consider 
implementing MAT programming in various settings. Our data indicates that there 
is a group that is collectively unaware of the studies on MAT. Moreover, if a 
respondent reported being unaware of studies on a particular use of MAT in their 
population, they were also less likely to report willingness to consider 
implementing MAT. Considering lack of knowledge contributes to a negative 
stance on MAT, and our finding that there appears to be a cohesive group that is 
not aware of the literature on MAT, a simple knowledge dissemination 
intervention could be employed, targeted to this group, to effectively alter this. 
Friedmann, in his 2006 and 2012 studies, reported important roles for 
knowledge in implementation of evidence-based practice.(61, 75) In their 2012 
study, his group found that a respondents’ stated lack of knowledge about MAT 
was associated with a lack of implementation at that respondent’s facility. 
Conversely, in 2006, reported knowledge was reported to be positively correlated 
with implementation of EBP. In 2012, they found that stated knowledge about 
MAT was the only factor positively associated with an interest in the future 
implementation of MAT-based programming. Although “knowledge” as we 
measured it did not take as primary a role in predicting this in our study, the co-
linearity of knowledge and attitudes points to a common pathway and a clear 
importance of both knowledge and its influence on attitudes. 
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Limitations 
The main limitation of this study lies in response rate. As mentioned in the 
methods section, response rates of organizations tend to be lower(73), and may 
be lower for the above reasons. Furthermore, a large study of surveys conducted 
by academic centers (as opposed to private or corporate survey entities) 
revealed an average response rate of 55.9% over the years 1975-1995, with a 
decline in average response rate over the years (average response rate was 
down to 48.4% in 1995). The subset of academic surveys of administrators or of 
organizations fared far worse than average with a mean response rate of 
36.1%.(80) Considering this, the obtained response rate (54.9%) was 
comparatively optimal for studies of its kind. However, 45.1% of those surveyed 
did not respond and the possibility of bias in the results obtained is very real. 
There are many reasons that response in this study may have been limited.  
One major confounding factor in this analysis is that two out of the five 
largest state correctional administrations (composing 12.9% of the total random 
sample) declined to respond to the survey because of decisions made by the 
research review board in each state. Had these large departments contributed a 
response, no significant difference in regional response rate would have been 
observed, and the total response rate would have reached 67.8%. The inclusion 
of responses from these large institutions would also potentially have had 
significant effect on the final analysis if their responses differed from other 
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respondents’ in their respective regions. Thus, their absence may point to a 
significant response bias. 
The content of the survey itself may have been an impediment to 
response rate. One comment received from many participants was that the 
survey itself was too lengthy and time consuming to complete. Many respondents 
also noted that it was too wide-ranging for one person to complete – the 
expertise of multiple members of an organization would be called upon to give 
accurate responses and this resulted in greater strain than anticipated.  
We also asked questions that were possibly viewed as possibly 
confidential information – we often received incomplete or absent data for our 
questions about budgets and substance abuse outlays within them as well as for 
our questions about methadone knowledge and attitudes. This is likely a 
manifestation of one of the liabilities of organizational surveying identified by 
Tomaskovic, et al. As correctional agencies are highly hierarchical, individuals 
within them were less likely to be “empowered … to have the authority to 
respond” to such questions within our survey.(73) Furthermore, this 
organizational restriction on individual empowerment seems to permeate the 
overarching structure within which local correctional units operate: many units 
declined to respond because they were limited by state structures and some 
units’ responses were received as a part of a larger response from an over-
arching state agency. 
Organizational heterogeneity between state correctional agencies and 
between the three main kinds of correctional organizations that we surveyed 
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made it difficult to obtain responses because the appropriate respondent in each 
organization was not analogous across organizations (i.e. the “Director of Inmate 
Services” would be the appropriate respondent at one organization where the 
“Health Services Manager” would be the appropriate respondent at another 
location). In general, this made targeting of the survey difficult and so we relied 
on the organization to direct the survey to the appropriate respondent(s) within 
their structures. Often, the complexity of our survey was thus an impediment to 
receipt of a response; multiple respondents were necessary in many 
organizations and this resulted in many surveys “falling through the cracks” 
between individuals and certainly contributed to the low response rate. 
 Budget cuts all around the country in state budgets as well as in 
correctional systems’ substance abuse treatment services (including the 
defunding of Proposition 36 in California) (79) have decimated state-funded drug 
abuse treatment.  One commentator on the aftermath of these cuts remarked, “I 
think that policy makers now understand the cost benefits of treatment, but are 
trying to cope with a massive short term deficit,” (79) indicating that budget 
deficits there have overridden the positive gains in knowledge and attitudes that 
came with new programming. 
This sentiment is reflected in our responses. It also may have played a 
role in increasing the difficulty of obtaining responses from our sample. Many of 
the respondents had to be emailed and called many times in order to obtain a 
response and often, these responses were incomplete. Several large agencies 
refused entirely to participate because of staff and resource limitations. 
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 Other factors may have also influenced response, such as bias for 
substance abuse treatment in corrections compared to no treatment. This 
possibility is supported by the fact that 100% of respondents said that they feel 
that substance abuse treatment programming has a place in the correctional 
system, and rated substance abuse treatment in the correctional system as a 
9.25/10 in importance. It is possible that potential respondents who feel that 
treatment does not belong in the correctional system did not respond and that a 
significant proportion of non-respondents would have given a different response. 
Given the proven efficacy of and need for substance abuse treatment in 
corrections and the strong mandate from national organizations,(66, 67) this 
seems less likely, however. 
 
Future Directions 
In sum, our research, taken alongside other recent surveys exploring 
factors related to the availability of evidence-based practice, points to the 
necessity of testing and implementing several simultaneous approaches to 
ensconcing the place of EBP in the correctional environment. Firstly, SAT 
programming should be preserved as a distinct line in correctional budgets. The 
primacy of the issue of substance abuse in correctional populations is a clear 
argument for this and our data indicates that SAT-specific funding increases are 
independently related to robust treatment programming implementation.  
Secondly, an educational program for correctional administrators should 
be devised and piloted with the aim of improving attitudes towards MAT and EBP 
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based at least in some part in knowledge dissemination. Alongside this should be 
a further study of the underlying aspects of positive and negative attitudes, with 
the results of these informing interventions. It is well-understood that factual 
knowledge itself is often not sufficient to encourage behavioral change and that 
providing an experiential understanding of MAT in a correctional setting may 
positively contribute to this effort of raising attitudes about MAT. This study of 
institutional and individual change would additionally be of broader interest and 
applicability to those working towards change in other large, entrenched 
organizations. 
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Appendix 1: Survey Instrument 
Key Terms 
 
 
Substance use disorders – Addiction to or dependence on illegal drugs like opiates (heroin), stimulants 
(methamphetamine, cocaine), or legal drugs like alcohol or prescription drugs (oxycontin, valium). 
 
Medication-Assisted Therapy (abbreviated MAT) – Treatment for substance use disorders that centers on 
medications.  Examples: Buprenorphine, methadone, naltrexone. 
 
Screening – Looking for the possible presence of a Substance Abuse condition BUT not assigning clinical 
designations. 
 
Assessment – Performed by a trained, experienced professional resulting in a clinical diagnosis 
 
 
 
 
Section 1: Background Information 
          
    
   Facility Attributes 
 
 
   F1. What is the average daily population of  your facility or probation/parole office  in 2009?  
       Please use complete figures from 2009 
 
a.  Number of administrators:  
b.  Total number of staff (include part and full time):  
c.  Average daily census of inmates:  
d.  Number of facilities or offices (Circle one) :     1-3    3-5    5-7     >7 
e.  Number of offenders released on parole/probation/supervision for whom your staff are responsible:   
 
  
   F2. What is your ideal maximum capacity?  
       Please sum the official capacities of all buildings in your system 
              
   _____________ 
 
  F3. What was your total annual operating budget for 2008-09?   
       Please round to the nearest $1,000 
  $__________ 
 
  F4a. What is the dollar amount of your annual operating budget in 2008-09 that was allocated specifically for treatment       
        of substance abuse/dependance disorders?  
 
        approx $____________ 
 
  F4b. Since 2006, has this amount: 
 
             1. Increased by approximately $____________ 
             2. Decreased by approximately $____________ 
             3. Stayed about the same (Check)   
 
 
 
Section 2: Current Practices 
 
  C1.  Does your facility currently offer substance abuse treatment services?        
       (Circle)       Y / N          
       If yes, continue to question C2.  If no, skip to question C5, below 
 
  C2. Is there a standardized system by which eligibility for substance abuse treatment services is determined? 
       (Circle)     Y  / N   
 
  C3. Is there a standardized system by which referral to treatment is made?  
         (Circle)     Y  / N 
 
  C4.  Which of the following characteristics influences who gets these services: 
 
a. Severity of the offender’s addiction? (Circle)       Y / N            
b. Length of stay of the offender? (Circle)       Y / N            
c. Presence of mental illness? (Circle)       Y / N            
d. Interest on the part of offenders? (Circle)       Y / N 
e. Other, indicate:  
 
   C5.  Below is a list of common activities between agencies. Please check all activities that apply to your working relationship with  
           treatment programs, the judiciary, and other criminal justice agencies on issues specific to offender substance abuse treatment.  
                
      (Check   all that apply for each row)  
 
 Substance abuse  treatment programs Judiciary 
Jail/prison or
a. 
 community 
corrections 
We share information on offender needs for 
treatment services 1 2 3 
b. Our organizations have agreed to similar 
requirements for program eligibility for some 
programs 
1 2 3 
c. We have written agreements providing space 
for substance abuse services for some 
programs 
1 2 3 
d. We hold joint staffings/case reporting 
consultations 1 2 3 
e. We have developed joint policy and procedure 
manuals 1 2 3 
f. Our organizations have pooled funding for 
some offender substance abuse services 1 2 3 
g. We have modified some program/service 
protocols to meet the needs of each agency 1 2 3 
h. We share budgetary oversight of some 
treatment programs 1 2 3 
i. We share operational oversight of some 
treatment programs 1 2 3 
j. Our organizations cross-train staff on 
substance abuse issues 1 2 3 
k. We have written protocols for sharing offender 
information 1 2 3 
 
 C6. Do you currently provide methadone maintenance therapy for offenders who meet criteria for opioid       
       dependence:   (Circle)     Y  /  N 
If yes, please go on to question C7.  If no, please skip to question C9a, below. 
 
                           C7. How many offenders per year receive methadone maintenance? ___________ 
             C8a.  Are you generally satisfied with methadone treatment?     (Circle)     Y  /  N 
              C8b.  Does your organization have substance abuse treatment-related performance-based contracting in place?  
                                            (Circle)     Y  /  N 
              C8c.  Does your organization receive free methadone in exchange for providing services?     (Circle)     Y  /  N 
              C8d.  Are there guaranteed slots in community clinics that are set aside for individuals treated with methadone  
                                      maintenance in your system?        (Circle)     Y  /  N 
           
Please indicate which of the following apply to why you don’t provide methadone maintenance therapy: 
                     
                   C9a.   There are not offenders in our system who have been dependent on opioids (heroin, prescription pain   
                               killers, methadone)    (Circle)       Y / N 
                    C9b.   Licensing regulations to prescribe methadone are too costly   (Circle)        Y / N 
                    C9c.   Methadone is too highly regulated and thus providing it would be very difficult   (Circle)       Y / N 
                    C9d.   Methadone would be too easily diverted and abused within our system      (Circle)      Y / N 
 
       C10. Do you currently provide buprenorphine (BPN) treatment for offenders who meet criteria for opioid      
       dependence:     (Circle)     Y  /  N 
If yes, please go on to question C11.  If no, please skip to question C13a, below. 
 
             C11. How many offenders per year receive buprenorphine (BPN) ___________ 
            C12a.  Are you generally satisfied with BPN treatment?     (Circle)     Y  /  N 
  C12b. Does your organization have substance abuse treatment-related performance-based contracting in place?  
                                            (Circle)     Y  /  N 
  C12c. Does your organization receive free buprenorphine in exchange for providing services?  (Circle)    Y  /  N 
  C12d. Are there guaranteed slots in community clinics that are set aside for individuals treated with BPN in  
                                       your system?   (Circle)     Y  /  N 
 
Please indicate which of the following apply to why you don’t provide BPN: 
                     
                    C13a.    There are not offenders in our facilities who have been dependent on opioids (heroin, prescription pain  
                                  killers, methadone)   (Circle)      Y / N 
                    C13b.    Licensing regulations to prescribe BPN are too costly   (Circle)        Y / N  
                    C13c.    BPN is too highly regulated and thus providing it would be very difficult   (Circle)       Y / N 
                    C13d.    BPN would be too easily diverted and abused within our system    (Circle)       Y / N 
 
 
 
    C14. Do you currently provide naltrexone treatment for offenders who meet criteria for alcohol dependence:  
 (Circle)     Y  /  N 
If yes, please go on to question C15.  If no, please skip to question C17a, below. 
 
              C15. How many offenders per year receive naltrexone in the:   
                     a. Oral Form (ReVia) _________ b. Injectable Form (Vivitrol)_________ 
 C16a.  Are you generally satisfied with naltrexone treatment?     (Circle)     Y  /  N 
  C16b. Does your organization have substance abuse treatment-related performance-based contracting in place?  
                                            (Circle)     Y  /  N 
  C16c.  Does your organization receive free naltrexone in exchange for providing services?     (Circle)     Y  /  N 
  C16d.  Are there guaranteed slots in community clinics that are set aside for individuals treated with  
                                        naltrexone in your system?        (Circle)     Y  /  N 
                
               If no, please briefly describe why you don’t provide naltrexone: 
        
                            C17a. Cost of drug is prohibitive    (Circle)        Y / N 
                            C17b. Personnel limitations (needs to be given by medical staff)     (Circle)        Y / N 
                            C17c.  Other ________________________________________ 
 
 
   C18. By your estimation, have there been any significant change in staffing levels recently within your correctional    
         system?  
 
         (Circle)     Y  /  N      
 
         (If yes, continue to C19.  If no, skip to question C20) 
 
   C19. Please check the appropriate box next to each staff type 
 
 
Staffing type Increased Unchanged Decreased 
a. Administrative staff—management 2 1 0 
b. Administrative staff—support 2 1 0 
c. In your prison/jail facility, corrections/custody/security staff 2 1 0 
d. Clinical staff—management 2 1 0 
e. Substance abuse assessment staff (who do not do counseling) 2 1 0 
f. Substance abuse clinical staff (include assessors if they also do counseling) 2 1 0 
g. Other clinical staff (social workers, vocational or mental health 
counselors, etc.) 
2 1 0 
h. Case managers/resource brokers 2 1 0 
 
   C20.  In the past two years, have any substance abuse treatment programs in your organization...  
          Please  all that apply 
         2 Been closed?  1 Had treatment beds or slots reduced?   0 Neither     
        If neither, skip to question 23 
   C21.  If there has been a reduction, identify up to three factors that contributed most to the reduction   
  Choose up to three factors from the list below 
 
       1  Funding cuts due to state deficit or other budget problems  
       2  Low offender buy-in for drug treatment programs  
       3  Failure of programs to achieve success  
       4  New legislation/policy prevented further use of treatment  
       5  Too many offenders with mental health problems  
       6  Leadership dissatisfaction with treatment program(s) 
       7  Not enough offenders eligible for program(s)  
 8  Offenders not in facility long enough to justify treatment 
 9  Offenders in facility for too long to justify treatment; use detoxification instead 
 10 Prefer drug-free method over MAT 
 11 No proof that MAT works in your population of offenders 
       12  Released individuals with substance abuse/dependence in prison to the community to save costs on treatment 
       13  Insufficient space for treatment programs  
       14  Other  (specify)_____________________  
 
   C22. With the factors listed above in question C21 in mind, please rank them using the scale below to indicate their influence          
            on your programming.   
           1 – Presents a major problem 
 2 – Presents a minor problem 
 3 – Presents no problem at all 
 4 – Can’t say either way  
 
Factor Rank  
a. Funding cuts due to state deficit or other budget problems   
b. Low offender buy-in for drug treatment programs  
c. Failure of programs to achieve success   
d. New legislation/policy prevented further use of treatment  
e. Too many offenders with mental health problems   
f. Leadership dissatisfaction with the treatment program  
g. Not enough offenders eligible for the program  
h. Offenders not in facility long enough to justify treatment  
i. Offenders in facility for too long to justify treatment; use detoxification instead  
j. Prefer drug-free method over MAT  
k. No proof that MAT works in your population  
l. Released individuals with substance abuse/dependence in prison to the community to 
save costs on treatment  
m. Insufficient space for treatment programs  
n. Other  (specify)_____________________   
    
   C23.  In the past two years, have any substance abuse treatment programs in your organization...   
             (  all that apply) 
        2  Been opened?   1 Had treatment beds or slots increased?  0  Neither 
            If neither, skip to question 23 
 
 
   C24.  If so, identify up to three factors that contributed most to programs being opened or increased:  
             Check next to up to three factors on the list below 
 
        1  New funding from federal agencies  
        2 New funding from state government  
        3 Positive attitude of correctional staff toward treatment programs  
        4 Excess number of offenders needing treatment services  
        5 New leadership that supports the expansion of treatment  
        6 Realization that treatment can reduce recidivism  
        7 Other  (specify)____________________ 
 
    C25. With the factors listed above in question C24 in mind, please rank them using the scale below to indicate their influence  
  on your programming.   
 
 1 – Major contributor to increase 
 2 – Minor contributor to increase 
 3 – Not a contributor to increase 
 4 – Can’t say either way  
 
Factor Rank  
New funding from federal agencies  
New funding from state government  
Positive attitude of correctional staff toward treatment programs   
Excess number of offenders needing treatment services  
New leadership that supports the expansion of treatment   
Realization that treatment can reduce recidivism  
 
Other  (specify)_____________________ 
 
 
 
 
Section 3: Perspectives About Current and Future Substance Abuse Treatment 
  
   P1. How would you assess the following potential barriers to implementing new programs/policies focused on           
       substance dependent offenders?     
 
       Please rank the barriers below in order of impact on your ability to implement new programming. When ranking, please  
        choose only one rank (along the top) per barrier (listed down the left-hand column). 
       Please fully check one box. Please do not check between boxes. 
    
 No barrier Slight barrier Moderate barrier Significant barrier 
a. Qualified staff 0 1 2 3 
b. Funding 0 1 2 3 
c. Leadership philosophy 0 1 2 3 
 No barrier Slight barrier Moderate barrier Significant barrier 
d. Staff attitudes 0 1 2 3 
e. Public attitudes 0 1 2 3 
f. Organizational capacity 0 1 2 3 
g. Physical space 0 1 2 3 
h. Other (Please specify)  ________________ 0 1 2 3 
 
    P2. Given the list of programs below, which barriers would present a major obstacle to implementation of new 
programs/policies focused on substance dependent offenders in your organization?   
 
       Please  the box next to each of  the program types (listed in the left-most column) and underneath the appropriate existing  
       barrier(s) (listed across the top).  
       Mark up to three barriers per program. If no barrier exists, please indicate that by checking the box under No barrier exists 
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Programs 
a. Narcotics or 
Alcoholics 
Anonymous 
 
1 

2 3 4 5 6 7 8 0 
b. Individual counseling  
1 

2 3 4 5 6 7 8 0 
c. Group counseling  
1 

2 3 4 5 6 7 8 0 
d. Medication to treat withdrawal  
1 

2 3 4 5 6 7 8 0 
e. Medication to provide maintenance 
therapy 
 
1 

2 3 4 5 6 7 8 0 
f. Medication to treat alcohol dependence  
1 

2 3 4 5 6 7 8 0 
g. Medication to treat cocaine dependence  
1 

2 3 4 5 6 7 8 0 
h. Medications plus counseling  
1 

2 3 4 5 6 7 8 0 
 
 
  P3. If all barriers to doing so were removed, would you like to add new treatment programs or increase capacity for substance 
dependent offenders in your facility? 
 
       Yes              No   
         If no, please skip to question P5 
 
 
 
 
    P4. What goals would you be satisfying if you were to implement new treatment programs for substance  
          dependent offenders? 
 
          Understanding that each item is important, please rank the choices in order of priority from 1 (highest) to 5 (lowest). We want to know    
          which of the goals holds most importance for your organization. Please only assign one rank per choice. 
 
         a. Reduced recidivism in your jurisdiction  ___ 
         b. Reduced substance use in facility  ___ 
         c. Rehabilitation of the offender ___ 
         d. Cost-Effectiveness  ___ 
         e. Other  (Please specify)  ________________________   ___ 
 
   P5. Now you will be asked to consider a list of possible treatment plans for substance abusing offenders. Indicate                
       whether you would implement, would consider implementing, or would not implement such a program.   
 
 
       Note: When giving your answers, imagine no restrictions on the possibility of implementing a program/policy.  
       Please only check one box below the appropriate option corresponding to each program type. 
       If you already provide the program, check Already Implemented 
        
Program  
Already 
Implemented 
Would 
Implement 
Would 
consider 
implementation 
Would not 
consider 
implementation 
currently 
a. Narcotics or alcoholics anonymous 3 2 1 0 
b. Individual counseling 3 2 1 0 
c. Group counseling 3 2 1 0 
d. Medication to treat opioid withdrawal (such as 
methadone or buprenorphine) 3 2 1 0 
e. Medication for opioid maintenance therapy (such as 
methadone or buprenorphine) 3 2 1 0 
f. Medication to treat alcohol dependence (such as 
naltrexone) 3 2 1 0 
g. Medication to treat cocaine dependence (such as 
antabuse) 3 2 1 0 
h. Medications (any medications used to treat substance 
disorders) plus counseling 3 2 1 0 
   
  P6.  Now you will be asked about the effectiveness of a list of possible treatment plans for substance abusing    
         offenders.   
        Please rank each program by the 6 point scale in the table below. Please choose only one rank per program type. 
 
Program 
Completely 
Ineffective 
Moderately 
ineffective 
Slightly 
Ineffective 
Slightly 
Effective 
Moderately 
Effective 
Completely 
Effective 
a. Narcotics or alcoholics anonymous 0 1 2 3 4 5 
b. Individual counseling 0 1 2 3 4 5 
c. Group counseling 0 1 2 3 4 5 
d. Medication to treat opioid withdrawal 0 1 2 3 4 5 
e. Medication to provide opioid 
maintenance therapy 0 1 2 3 4 5 
f. Medication to treat alcohol dependence 0 1 2 3 4 5 
g. Medication to treat cocaine dependence 0 1 2 3 4 5 
h. Medications plus counseling 0 1 2 3 4 5 
 
  P7. Now you will be asked to consider what has been shown by studies on each of these programs that have been performed in   
         the population you work with. 
 
             Please check next to each program under the descriptive category that best fits it. Please check one description per program. 
 
Program Shown to work Shown not to work 
Studies 
inconclusive 
Not sure of 
studies 
a. Narcotics or alcoholics anonymous 3 2 1 0 
b. Individual counseling 3 2 1 0 
c. Group counseling 3 2 1 0 
d. Medication to treat opioid withdrawal 3 2 1 0 
e. Medication to provide opioid maintenance therapy 3 2 1 0 
f. Medication to treat alcohol dependence 3 2 1 0 
g. Medication to treat cocaine dependence 3 2 1 0 
h. Medications plus counseling 3 2 1 0 
 
 
   P8. This series of questions has to do with how you view methadone in particular.  Please answer each question  
          with a “yes” or “no” based on your feelings about methadone. 
 
             Please     Y  /  N  
  Y  N 
a. Staff will restrict access to methadone to control offenders.   
b. No matter how many safeguards there are, offenders who aren’t supposed to receive methadone will get it.   
c. The safeguards built into the methadone program are adequate to prevent illicit use.   
d. The methadone program will increase medical problems.   
e. A methadone program will lead to fewer offender infractions.   
f. The potential for offender abuse outweighs the potential benefit of the methadone program.   
g. The methadone program will increase security risks.   
h. Heroin addicts should just quit. It doesn’t make much sense to use methadone.   
i. The way methadone is dispensed is so restricted that it’s not worth using.   
j. I admire people who join a methadone program to kick their heroin habit.   
k. I admire people who kick their heroin habit.    
l. The final goal of methadone treatment should be abstinence from all drugs.   
m. Methadone treatment substitutes one addictive drug for another.   
n. Making people go through withdrawal will teach them a lesson.   
o. It is not worth the money to use methadone; people will use drugs if they want to.   
 
   P9. The following questions are in regards to methadone as a treatment.  Please answer each question with a  
         “yes” or “no” based on what you know about methadone. 
 
          Please     Y  /  N 
 Y N 
a. Heroin addicts on methadone die at a younger age than people on heroin   
b. Methadone causes bone and tooth decay.   
 Y N 
c. Longer periods of methadone maintenance are better than shorter periods for preventing relapse.   
d. Methadone clients should not be allowed to operate heavy machinery or to drive a car.   
e. A maintenance dose of methadone gets people high.   
f. Methadone can treat alcohol and cocaine as well as heroin addiction.   
g. Heroin addiction is a moral weakness.   
h. Methadone can only be used safely for a short time.   
i. Heroin addiction is a disease.   
j. A methadone dose should be high enough to prevent withdrawal symptoms.   
k. People on methadone are too ‘‘zoned out’’ to work.   
l. When a woman on methadone becomes pregnant she should quit using it.   
m. Methadone is a drug that can be used for getting high.   
n. Methadone is the best treatment for heroin.   
o. You should use the lowest possible dose of methadone (for maintenance) or other dosing issues.   
 
 
   P10. On a scale of 1 (unimportant) to 10 (very important), rate the importance of providing  
        substance abuse treatment to offenders with substance abuse problems... 
 
       Write a number 1-10 on the line below 
 
        a. In prison ______          b. In the community ______          c. In prison and the community simultaneously _______ 
 
 
 
 
 
    P11a. Do you feel the corrections system should have a role in screening and treatment for substance abuse problems? 
 
       (Circle)     Y  /  N       
 
        P11b. Please briefly describe your answer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for your time and careful consideration of our questions.  Your help is greatly appreciated in our efforts to 
advance the health of our nation and its citizens. 
Page 11 out of 12 
 
  
Page 12 out of 12 
 
